Search

Your search keyword '"Hanau, Ahuva"' showing total 23 results
Start Over Author "Hanau, Ahuva"
23 results on '"Hanau, Ahuva"'

2. 1942. Potential Public Health Impact of Bivalent Respiratory Syncytial Virus Prefusion F (RSVpreF) Maternal Vaccine for Prevention of RSV among US Infants

Author

Hanau, Ahuva, primary, Shea, Kimberly M, additional, Weycker, Derek, additional, Atwood, Mark, additional, Quinn, Erin, additional, Kutrieb, Emily, additional, Atwell, Jessica E, additional, Cane, Alejandro D, additional, Gessner, Bradford J, additional, Pugh, Sarah J, additional, and Law, Amy W, additional

Published
2023
Full Text
View/download PDF

7. Abstract P2-08-24: Risk of chemotherapy-induced febrile neutropenia (FN) in patients with metastatic cancer of the breast or other sites not receiving colony-stimulating factor prophylaxis (CSF) in US clinical practice

Author

Weycker, Derek, primary, Silvia, Amanda, additional, Hanau, Ahuva, additional, Lamerato, Lois, additional, Richert-Boe, Kathryn, additional, Kaur, Manpreet, additional, Shah, Neel, additional, Hatfield, Mark, additional, and Lyman, Gary H, additional

Published
2020
Full Text
View/download PDF

14. COMPARATIVE EFFECTIVENESS OF APIXABAN VERSUS WARFARIN FOR TREATMENT OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH AND WITHOUT ACTIVE CANCER

Author

Wygant, Gail D., primary, Guo, Jennifer, additional, Rosenblatt, Lisa, additional, Weycker, Derek, additional, Li, Shawn, additional, Lee, Theodore, additional, Luo, Xuemei, additional, Mardekian, Jack, additional, Hanau, Ahuva, additional, Atwood, Mark, additional, Pan, Xianying, additional, and Cohen, Alexander (Ander), additional

Published
2019
Full Text
View/download PDF

17. Erratum: Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical Practice

Author

Weycker, Derek, additional, Li, Xiaoyan, additional, Wygant, Gail DeVecchis, additional, Lee, Theodore, additional, Hamilton, Melissa, additional, Luo, Xuemei, additional, Vo, Lien, additional, Mardekian, Jack, additional, Pan, Xianying, additional, Burns, Leah, additional, Atwood, Mark, additional, Hanau, Ahuva, additional, and Cohen, Alexander T., additional

Published
2018
Full Text
View/download PDF

18. Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical Practice

Author

Weycker, Derek, additional, Li, Xiaoyan, additional, Wygant, Gail DeVecchis, additional, Lee, Theodore, additional, Hamilton, Melissa, additional, Luo, Xuemei, additional, Vo, Lien, additional, Mardekian, Jack, additional, Pan, Xianying, additional, Burns, Leah, additional, Atwood, Mark, additional, Hanau, Ahuva, additional, and Cohen, Alexander T., additional

Published
2018
Full Text
View/download PDF

23. Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis: a retrospective evaluation using Medicare claims.

Author

Weycker, Derek, Hanau, Ahuva, Lonshteyn, Alexander, Bowers, Charles, Garawin, Tamer, Bensink, Mark, and Chandler, David

Subjects
*FEBRILE neutropenia, *GENERALIZED estimating equations, *DEFINITIONS, *MEDICARE, *CANCER chemotherapy, *ARTIFICIAL joints, *PREVENTIVE medicine
Abstract

Background: Two recent evaluations reported that many cancer chemotherapy patients discontinue pegfilgrastim prophylaxis (PP) following the first cycle, and that these patients have a higher subsequent risk of febrile neutropenia (FN). Such evidence is based principally on the experience of younger adults with private healthcare coverage, and the generalizability of results to elderly Medicare patients is unknown.Methods: A matched-cohort design and data from the Medicare Claims Research Identifiable Files were employed. The source population comprised cancer patients aged ≥65 years who received chemotherapy with intermediate/high-risk for FN and first-cycle PP. From the source population, beginning with the second cycle, all patients who received PP in all previous cycles were identified. From this sub-set, patients who did not receive PP in the cycle of interest ("comparison patients") were matched to those who received PP in that cycle ("PP patients"); the same process was repeated for subsequent cycles. Odds ratios (OR) for FN (broad and narrow definitions) were estimated using generalized estimating equations.Results: Among 77,616 elderly patients in the source population, 5.3% did not receive second-cycle PP and were matched to those who did. In cycle 2, FN odds were significantly higher among comparison patients vs PP patients when employing the broad definition (OR = 1.9, p < .001) and the narrow definition (OR = 2.1, p < .001). Results for subsequent cycles (broad definition: OR = 2.0, p < .001; narrow definition: OR = 2.1, p < .001) and for the last cycle (broad definition: OR = 1.4, p = .060; narrow definition: OR = 1.7, p = .055) were largely comparable.Conclusions: In this large-scale evaluation of elderly Medicare patients who received myelosuppressive chemotherapy and first-cycle PP in recent US clinical practice, FN risk was substantially lower among patients who continued to receive PP in subsequent cycles vs those who discontinued PP. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results